Investors sentiment decreased to 1.29 in 2019 Q2. Its down 0.07, from 1.36 in 2019Q1. It dived, as 7 investors sold Cytosorbents Corporation shares while 17 reduced holdings. 11 funds opened positions while 20 raised stakes. 7.96 million shares or 1.03% less from 8.04 million shares in 2019Q1 were reported.
North Carolina-based Financial Bank Of America De has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Papp L Roy And Assoc has 0.01% invested in Cytosorbents Corporation (NASDAQ:CTSO). Granite Inv Prns Ltd Com has invested 0.01% in Cytosorbents Corporation (NASDAQ:CTSO). California State Teachers Retirement Systems accumulated 0% or 46,733 shares. Fmr Limited Company stated it has 69 shares or 0% of all its holdings. Voya Invest Management Lc reported 14,693 shares. Crow Point Limited Liability owns 45,361 shares for 0.05% of their portfolio. 3,500 were accumulated by Advisory Networks Limited Com. Avenir invested 0.1% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Deutsche Natl Bank Ag holds 0% or 23,936 shares in its portfolio. 38,055 were accumulated by Morgan Stanley. Rhumbline Advisers reported 38,827 shares. 5,023 are held by Legal General Gru Incorporated Public Ltd Com. Citigroup accumulated 8,577 shares. Ny State Common Retirement Fund stated it has 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO).
Since August 16, 2019, it had 2 insider buys, and 0 insider sales for $35,665 activity.
The stock of Cytosorbents Corporation (NASDAQ:CTSO) is a huge mover today! The stock decreased 2.96% or $0.115 during the last trading session, reaching $3.77. About 117,528 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 40.00% since December 4, 2018 and is downtrending. It has underperformed by 40.00% the S&P500.
The move comes after 9 months negative chart setup for the $122.24M company. It was reported on Dec, 4 by Barchart.com. We have $3.43 PT which if reached, will make NASDAQ:CTSO worth $11.00 million less.
Analysts await Cytosorbents Corporation (NASDAQ:CTSO) to report earnings on March, 5. They expect $-0.17 EPS, 0.00 % or $0.00 from last year’s $-0.17 per share. After $-0.21 actual EPS reported by Cytosorbents Corporation for the previous quarter, Wall Street now forecasts -19.05 % EPS growth.
More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Prnewswire.com which released: “CytoSorbents Highlights Recent Published Studies on CytoSorb – PRNewswire” on August 28, 2019, also Prnewswire.com with their article: “World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis – PRNewswire” published on September 13, 2019, Prnewswire.com published: “CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock – PRNewswire” on September 25, 2019. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Nasdaq.com and their article: “U.S. STOCKS ON THE MOVE-General Electric, Cymabay, TD Ameritrade, Uber – Nasdaq” published on November 25, 2019 as well as Seekingalpha.com‘s news article titled: “CytoSorbents expands CytoSorb distribution in Latin America – Seeking Alpha” with publication date: August 13, 2019.
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $122.24 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.